x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:38:31

Expert Insights on Highlights From ASH 2020 on...

Decera Clinical Education Oncology Podcast ·

2021/03/12

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:Newly diagnosed multiple myelomaRelapsed/refractory multiple myelomaAnti-BCMA therapy: CAR T-cellsAnti-BCMA therapy: bispecific antibodiesAnti-BCMA therapy: antibody–drug conjugatesNovel targeted agents for relapsed/refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy

en

00:26:19

Expert Insights on Key Data From ASH 2020 on Acute...

Decera Clinical Education Oncology Podcast ·

2021/02/26

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include: The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research

en

00:15:12

Expert Insight on Key Data From WCLC 2020 in...

Decera Clinical Education Oncology Podcast ·

2021/02/24

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinibAn analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistanceFDG PET/CT adaptive radiotherapy in RTOG 1106The TALENT study in Taiwan screening nonsmokers for lung cancerPresenter:Jamie E. Chaft,

en

00:21:16

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2021/02/22

In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective. Presenters:José Ignacio Nolazco, MD Urology FellowHospital Universitario AustralBuenos Aires, ArgentinaAlejandro Nolazco, MDAssociate ProfessorDepartment of UrologyUniversidad Austral and Universidad Católica ArgentinaBuenos Aires, ArgentinaContent based on an online IME program supported by

en

00:40:17

Expert Insights on Key Data From ASH 2020 on...

Decera Clinical Education Oncology Podcast ·

2021/02/10

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory

en

00:23:43

Expert Insights on Key Data From ASH 2020 on...

Decera Clinical Education Oncology Podcast ·

2021/02/05

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 studyA post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV studyPhase

en

00:25:33

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2021/02/04

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Guiseppe Procopio, MD Head of the Medical Oncology Genitourinary, Istituto Nazionale TumoriMedical OncologyFondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyCora N. Sternberg, MD, FACPProfessor of MedicineDepartment of Hematology/OncologyWeill Cornell MedicineNew York, New York, USAContent based on an online

en

00:28:07

Expert Answers to Questions on Contemporary...

Decera Clinical Education Oncology Podcast ·

2021/02/04

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:Maintaining long-term musculoskeletal healthIdentifying patients most likely to benefit from pharmacokinetics-guided prophylaxisManaging combination therapies in older patients with comorbiditiesYoungest age at which patients can be considered for emicizumabDevelopment of resistance to emicizumabSwitching

en

00:28:05

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2021/02/01

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune

en

00:23:06

An Expert Overview of Immunotherapy for Advanced HCC

Decera Clinical Education Oncology Podcast ·

2021/01/19

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of nivolumab ± ipilimumab and pembrolizumabEmerging immunotherapy combinations currently being investigated in clinical

en

00:23:13

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2021/01/08

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Félix Guerrero Ramos, MD, PhD, FEBU Teaching CollaboratorDepartment of SurgeryMedicine SchoolUniversidad Complutense de MadridAttending UrologistDepartment of UrologyUroOncology UnitMadrid, Spain Óscar Rodríguez-Faba, MD UrologistUro-OncologyFundació PuigvertBarcelona, Catalonia, SpainContent based on an

en

00:14:32

Expert Answers to Pathologist Questions on New...

Decera Clinical Education Oncology Podcast ·

2020/12/28

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistancePerforming biomarker testing on cytology vs surgical or anatomic pathology specimensFactors affecting turnaround time when testing liquid biopsy vs tissue

en

00:21:49

Application of Individualized Treatment for CLL/SLL:...

Decera Clinical Education Oncology Podcast ·

2020/12/24

In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.Presenters:William G. Wierda, MD, PhD, Program DirectorProfessor of MedicineChief, Section of CLLDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasJeremy S. Abramson, MD, MMScAssociate ProfessorDepartment of

en

00:25:45

Practical Insights on Key Data From ESMO 2020...

Decera Clinical Education Oncology Podcast ·

2020/12/21

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrenceBiomarker testing in early-stage lung cancer New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated

en

00:22:38

Immunotherapy for Advanced HCC: Experts Answer...

Decera Clinical Education Oncology Podcast ·

2020/12/17

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver functionUse of biomarkers to

en

00:14:21

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2020/11/20

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settingsUtility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapyResults from the

en

00:18:07

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2020/11/19

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Alain Ravaud, MD, PhD Professor of Medical OncologyHead of Department of Medical OncologyBordeaux University HospitalBordeaux, FranceMarine Gross-Goupil, MD, PhD Medical OncologistSaint-André HospitalBordeaux University HospitalBordeaux, FranceContent based on an online IME program supported by educational grants from

en

00:17:02

Molecular Classification of Endometrial Carcinoma in...

Decera Clinical Education Oncology Podcast ·

2020/11/11

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer. Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University

en

00:22:39

Advances in Immunotherapy for Endometrial Cancer

Decera Clinical Education Oncology Podcast ·

2020/11/11

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, Denmark Content based on an online CME program

en

00:07:53

Developments in Acute Leukemias: Expert Answers to...

Decera Clinical Education Oncology Podcast ·

2020/10/02

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:MRD in the management of ALLTherapy choice for older patients with AMLOptimal use of inotuzumab ozogamicin and blinatumomab for ALLUse of CAR T-cell therapy for acute leukemiasContent based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program:https://bit.ly/3jiCBaD

en

224 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College